Jonathan Duffy1, Eric Weintraub2, Simon J Hambidge3, Lisa A Jackson4, Elyse O Kharbanda5, Nicola P Klein6, Grace M Lee7, S Michael Marcy8, Cynthia C Nakasato9, Allison Naleway10, Saad B Omer11, Claudia Vellozzi2, Frank DeStefano2. 1. Immunization Safety Office, US Centers for Disease Control and Prevention, Atlanta, Georgia; jduffy@cdc.gov. 2. Immunization Safety Office, US Centers for Disease Control and Prevention, Atlanta, Georgia; 3. Institute for Health Research, Kaiser Permanente Colorado and Ambulatory Care Services, Denver Health, Denver, Colorado; 4. Group Health Research Institute, Seattle, Washington; 5. HealthPartners Institute for Education and Research, Minneapolis, Minnesota; 6. Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California; 7. Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts; 8. Kaiser Permanente Southern California, Pasadena, California; 9. Kaiser Permanente Hawaii, Honolulu, Hawaii; 10. Kaiser Permanente Northwest, Portland, Oregon; and. 11. Kaiser Permanente Georgia, Atlanta, Georgia.
Abstract
BACKGROUND AND OBJECTIVE: An increased risk of febrile seizure (FS) was identified with concomitant administration of trivalent inactivated influenza vaccine (IIV3) and pneumococcal conjugate vaccine (PCV) 13-valent during the 2010-2011 influenza season. Our objective was to determine whether concomitant administration of IIV3 with other vaccines affects the FS risk. METHODS: We examined the risk of FS 0 to 1 day postvaccination for all routinely recommended vaccines among children aged 6 through 23 months during a period encompassing 5 influenza seasons (2006-2007 through 2010-2011). We used a population-based self-controlled risk interval analysis with a control interval of 14 to 20 days postvaccination. We used multivariable regression to control for receipt of concomitant vaccines and test for interaction between vaccines. RESULTS: Only PCV 7-valent had an independent FS risk (incidence rate ratio [IRR], 1.98; 95% confidence interval [CI], 1.00 to 3.91). IIV3 had no independent risk (IRR, 0.46; 95% CI, 0.21 to 1.02), but risk was increased when IIV3 was given with either PCV (IRR, 3.50; 95% CI, 1.13 to 10.85) or a diphtheria-tetanus-acellular-pertussis (DTaP)-containing vaccine (IRR, 3.50; 95% CI, 1.52 to 8.07). The maximum estimated absolute excess risk due to concomitant administration of IIV3, PCV, and DTaP-containing vaccines compared with administration on separate days was 30 FS per 100 000 persons vaccinated. CONCLUSIONS: The administration of IIV3 on the same day as either PCV or a DTaP-containing vaccine was associated with a greater risk of FS than when IIV3 was given on a separate day. The absolute risk of postvaccination FS with these vaccine combinations was small.
BACKGROUND AND OBJECTIVE: An increased risk of febrile seizure (FS) was identified with concomitant administration of trivalent inactivated influenza vaccine (IIV3) and pneumococcal conjugate vaccine (PCV) 13-valent during the 2010-2011 influenza season. Our objective was to determine whether concomitant administration of IIV3 with other vaccines affects the FS risk. METHODS: We examined the risk of FS 0 to 1 day postvaccination for all routinely recommended vaccines among children aged 6 through 23 months during a period encompassing 5 influenza seasons (2006-2007 through 2010-2011). We used a population-based self-controlled risk interval analysis with a control interval of 14 to 20 days postvaccination. We used multivariable regression to control for receipt of concomitant vaccines and test for interaction between vaccines. RESULTS: Only PCV 7-valent had an independent FS risk (incidence rate ratio [IRR], 1.98; 95% confidence interval [CI], 1.00 to 3.91). IIV3 had no independent risk (IRR, 0.46; 95% CI, 0.21 to 1.02), but risk was increased when IIV3 was given with either PCV (IRR, 3.50; 95% CI, 1.13 to 10.85) or a diphtheria-tetanus-acellular-pertussis (DTaP)-containing vaccine (IRR, 3.50; 95% CI, 1.52 to 8.07). The maximum estimated absolute excess risk due to concomitant administration of IIV3, PCV, and DTaP-containing vaccines compared with administration on separate days was 30 FS per 100 000 persons vaccinated. CONCLUSIONS: The administration of IIV3 on the same day as either PCV or a DTaP-containing vaccine was associated with a greater risk of FS than when IIV3 was given on a separate day. The absolute risk of postvaccination FS with these vaccine combinations was small.
Authors: Emmanuel B Walter; Nicola P Klein; A Patricia Wodi; Wes Rountree; Christopher A Todd; Amy Wiesner; Jonathan Duffy; Paige L Marquez; Karen R Broder Journal: Pediatrics Date: 2020-02-06 Impact factor: 7.124
Authors: Shirley V Wang; Abdurrahman Abdurrob; Julia Spoendlin; Edwin Lewis; Sophia R Newcomer; Bruce Fireman; Matthew F Daley; Jason M Glanz; Jonathan Duffy; Eric S Weintraub; Martin Kulldorff Journal: Pharmacoepidemiol Drug Saf Date: 2018-02-13 Impact factor: 2.890
Authors: Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark Journal: MMWR Recomm Rep Date: 2018-04-27
Authors: Shirley V Wang; Kristina Stefanini; Edwin Lewis; Sophia R Newcomer; Bruce Fireman; Matthew F Daley; Jason M Glanz; Jonathan Duffy; Eric Weintraub; Martin Kulldorff Journal: Drug Saf Date: 2020-10 Impact factor: 5.606
Authors: Emmanuel B Walter; Christoph P Hornik; Lisa Grohskopf; Charles E McGee; Christopher A Todd; Oidda I Museru; Lynn Harrington; Karen R Broder Journal: Vaccine Date: 2017-10-19 Impact factor: 3.641
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Joseph S Bresee; Alicia M Fry; Daniel B Jernigan Journal: MMWR Recomm Rep Date: 2017-08-25